TRIANNI partners with other companies interested developing therapeutic monoclonal antibodies by utilizing our proprietary platform – The Trianni Mouse. Licensing is available directly or through CROs for use in their antibody discovery solutions. Contact us for more information.
TRIANNI’s Discovery Partners include several medium-large pharma partners. Below is representative of those that are publicly announced.
Trianni, Inc holds licensing agreements with Massachusetts General Hospital, Stanford University, University of Alabama, Birmingham and those listed below.
Recent Comments